FDA Authorizes Four NJOY Ace E-Cigarette Products

Apr.27.2022
FDA Authorizes Four NJOY Ace E-Cigarette Products
FDA approves NJOY Ace e-cigarette and three tobacco-flavored e-liquids for legal sale in the US.

On April 26th, the FDA announced its decision regarding several electronic cigarette products from NJOY Ace, which includes authorizing four new tobacco products through the premarket tobacco product application (PMTA) pathway. The FDA issued a marketing authorization order to NJOY LLC for their Ace closed system electronic cigarette device and three companion tobacco-flavored e-liquid pods, as follows:

 

NJOY Ace device.

 

The NJOY Ace Pod Classic Tobacco 2.4% is a tobacco-flavored vaping pod.

 

The NJOY Ace Pod Classic Tobacco 5 is a tobacco-flavored vape pod made by NJOY.

 

The NJOY Ace Pod in Rich Tobacco, containing 5% nicotine.

 

This authorization allows these products to be sold legally in the United States. Although this action permits the sale of these particular products in the U.S., it does not mean that they are safe or FDA-approved. All tobacco products are harmful and can be addictive. Those who do not use tobacco products should not start using them.

 

The US Food and Drug Administration has issued a marketing denial order to NJOY for several of its flagship electronic cigarette products. Any of these products currently on the market must be removed, or the FDA may take enforcement action. Retailers with questions regarding their inventory should contact NJOY. Applications for two mint-flavored Ace electronic liquid pods are still under FDA review.

 

According to the PMTA process, applicants must demonstrate to the agency that the marketing of their new tobacco products is appropriate for protecting public health, among other requirements. The authorized NJOY product is believed to meet this standard because chemical testing has shown that the overall levels of harmful and potentially harmful constituents (HPHCs) in their aerosol are lower than those found in cigarette smoke. Additionally, data provided by the applicant indicates that participants who only used the authorized NJOY Ace product were exposed to lower levels of HPHCs compared to dual users of new products and cigarettes. Therefore, these products have the potential to benefit adult smokers who completely switch or significantly reduce their cigarette consumption.

 

Furthermore, the FDA has considered the risks and benefits to the entire population, including both tobacco users and non-users, and most importantly, youth. This includes reviewing existing data on the potential for youth use of the product. For authorized products, the FDA believes that the potential benefits of significantly reducing or completely ceasing smoking among adult smokers outweigh the risks to youth if the company complies with post-market requirements to reduce youth exposure and marketing.

 

In addition, the authorization imposes strict marketing restrictions on the company to greatly reduce the possibility of youth exposure to tobacco advertisements for these products. The Food and Drug Administration will closely monitor the marketing methods of these products and will take necessary action if the company fails to comply with any applicable legal or regulatory requirements or if the number of non-smokers (including youth) using these products increases significantly.

 

If the FDA determines that a product is no longer "appropriate for protecting public health" to continue being sold, for example, if there is a significant increase in the number of teenagers who start smoking, the FDA may suspend or rescind marketing approval issued under the PMTA pathway for various reasons.

 

The FDA must edit commercial secrets and confidential commercial information (CCI) before providing marketing decision documents to the public, and ensure that the files posted on the FDA website are available for everyone to read. For these reasons, the complete summary of the marketing authorization decision may not be posted on the webpage of the pre-market tobacco product marketing authorization order until after the order is issued. During this period, in order to provide as much information as possible at the time of the order, the FDA is providing an edited version of the order letter and the "executive summary" section of the decision summary, to broadly explain the public health reasons for authorizing these products.

 

Source: FDA official website.

 

The Food and Drug Administration (FDA) has made marketing decisions regarding Njoy Ace e-cigarette products.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
RLX Technology reported a 69.7% year-on-year increase in third-quarter 2026 revenue to RMB1.92 billion ($285.9 million), driven primarily by the consolidation of a newly acquired Western European distributor. International markets accounted for 86.5% of revenue. The acquisition followed RLX's RMB744 million purchase of controlling interests in UK vaping company Totally Wicked in 2025, expanding the group's directly controlled European retail and distribution operations. SEC filings also show that purchases from Shenzhen Smoore Technology Limited declined from 80% of RLX's total purchases in 2022 to 23% in 2025. Third-quarter gross margin fell to 23.3%, while GAAP operating income declined 57.7%.
Business
Nov.20
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
The White House withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration (FDA) on November 17, 2026, a day before a scheduled Senate committee vote. Overton faced questions from Republican and Democratic senators over vaccines, abortion medication and flavored nicotine products. In May, the FDA granted its first marketing authorizations for non-tobacco, non-menthol e-cigarette flavors, including mango and blueberry pods from Glas. Republican Senator Susan Collins challenged recent authorizations for flavored vaping and nicotine pouch products during Overton's September confirmation hearing. The FDA remains under Acting Commissioner Kyle Diamantas.
FDA
Nov.18
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii's Largest Independent Vape Retailer and Wholesaler Volcano to Close All 13 Stores Ahead of 2027 Sales Rules
Hawaii-based vaping company Volcano eCigs plans to close all 13 physical retail stores on December 31, 2026, affecting approximately 56 employees. Volcano operates retail, wholesale, proprietary product and online sales businesses and has previously described itself in legislative testimony as Hawaii's largest independent vape retailer and wholesaler. Its operating company, Jocor Enterprises LLC, filed a formal closure notice on November 4, citing changes in the state's regulatory environment. From January 1, 2027, Hawaii will restrict the sale, acquisition and possession of vaping devices and e-liquids not listed in a state product directory, alongside separate restrictions on certain disposable devices. The closure concerns Volcano's physical retail network; the company has not announced the termination of wholesale or online operations.
Market
Nov.09
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City Opens Lottery for 55 Vape Retail License Slots Across 23 Community Districts, Including 28 in Brooklyn
New York City's Department of Consumer and Worker Protection (DCWP) opened applications on November 2, 2026, for a lottery covering tobacco and electronic cigarette retail dealer licenses, with a deadline of 5 p.m. New York local time on November 30. According to the city's October 1 notice, 55 electronic cigarette retail license slots are available across 23 community districts, including 28 in Brooklyn, alongside 322 tobacco retail license slots across 41 districts. Businesses must enter the lottery and, if invited, complete licensing requirements within 65 days. New York City continues to restrict e-cigarette retail sales to tobacco-flavored or unflavored products, while city retail licenses do not replace FDA product marketing authorization.
Market
Nov.04